DRKS00023304
Completed
未知
A proof of concept study to evaluate the impact of a food supplement on uptake and anti-inflammatory properties of omega-3 fatty acid derived specialized pro-resolution lipid mediators - BTS1487/20
ConditionsHealthy volunteers
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Healthy volunteers
- Sponsor
- Evonik Operations GmbH
- Enrollment
- 19
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •BMI 25\-35,
- •Omega\-3 Index \< 6%,
- •Non\-smoker
Exclusion Criteria
- •(1\) Relevant history or presence of any severe medical disorder, potentially interfering with this study (e.g. mal absorption, chronic gastro\-intestinal diseases, heavy depression, diabetes, acute cancers within last 3 years except basal cell carcinoma of the skin, etc.)
- •(2\) Subject under prescription for medication or taking dietary supplements possibly interfering with this study (such as omega\-3 fatty acids, probiotics, anti\-spasmodic, laxatives and anti\-diarrheic drugs or other digestive auxiliaries, use of PPIs, bismuth salts and/or H2\-antagonists, fibers etc.) within 2 weeks prior to study start or during the study
- •(3\) Intake of antibiotics in the last 2 months and laxatives in the last 2 weeks
- •(4\) Significant changes in lifestyle or medication (within last 2 months) or surgical intervention or surgical procedure such as bariatric surgery
- •(5\) Subjects consuming
- •food or drinks claimed as ‘probiotic’ more than once weekly
- •more than 3 portions of fruits and vegetables (sum) per day
- •(6\) Subjects with stool frequency of \= 2 stools per week
- •(7\) Subjects with history of drug, alcohol or other substance abuse, or other factors limiting their ability to co\-operate during the study.
- •(8\) Relevant allergy or known hypersensitivity against compounds of the study preparations
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A proof of concept study to evaluate the impact of a food supplement on production of short chain fatty acids and microbiome in healthy subjectshealthy volunteersDRKS00023166Evonik Operations GmbH18
Active, not recruiting
Not Applicable
Proof of concept study to investigate the impact of BAY 58-2667 given intravenously in patients with acute decompensated chronic congestive heart failureEUCTR2005-004473-14-DEBayer HealthCare AG60
Active, not recruiting
Phase 1
A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects.MalariaInfection - Other infectious diseasesACTRN12614000781640James McCarthy8
Completed
Not Applicable
A Randomised, Double-blinded, Placebo-controlled Study of the probiotic PCC(Registered Trademark) (L. fermentum VRI-003) capsule for the effect on gastrointestinal health and gut microflora in healthy adults (with no medically diagnosed gastrointestinal disease)Gastrointestinal healthOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12616001052426Bioxyne Limited60
Withdrawn
Not Applicable
a pilot study into the effects and feasibility of the use of Tiscover® (tissue-engineered autologous skin substitute) for chronic ulcers (venous ulcers, diabetic ulcers and decubitus ulcers).decubitus/diabetic/ venous ulcers10040790NL-OMON30845Vrije Universiteit Medisch Centrum20